Get the Stockscreener App
2.99
1.97%
-0.06
Why is Vigil Neuroscience Inc (VIGL) Stock down?
We've noticed a 7.84% decline in Vigil Neuroscience Inc (VIGL) stock during the 2024-11-18 trading session. While this could be attributed to normal volatility or various internal and external factors, please be aware that we are actively monitoring the situation, and we'll provide timely updates as soon as possible!
17 Nov, 2023:
Vigil Neuroscience Stock (VIGL) dropped by 40.03% from $6.67 to $4.00 in the trading on Friday November 17, 2023. The reason why VIGL stock down today is due to the interim data from its Phase 2 IGNITE proof-of-concept clinical trial in patients with ALSP. The data, representing the first six patients following six months of treatment with 20 mg/kg of iluzanebart, supports the drug's safety and tolerability, and showed target engagement and downstream pharmacological activity, consistent with Phase 1 data. Directionally supportive changes were observed on MRI and NfL biomarkers of disease progression in individual patients, and the company expects to report full Phase 2 IGNITE results in Q3 2024.
1.80%
0.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):